Capital International Investors
Position in SYRE — Spyre Therapeutics, Inc.
CIK 1562230
Los Angeles, CA
Position in SYRE
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$88,074,746
-$26,340,897 QoQ
Shares Held
1,746,129
-50.0% QoQ
Ownership
2.01%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Capital International Investors holds $7,233,634,148 across 15 Biotechnology names. SYRE ranks #9 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
5,126,077 | $2,288,998,423 | |
| 2 | RPRX |
Royalty Pharma plc
|
35,005,736 | $1,679,225,155 | |
| 3 | ONC |
BeOne Medicines Ltd.
|
4,158,726 | $1,235,016,860 | |
| 4 | INSM |
INSMED Inc
|
5,595,194 | $914,926,122 | |
| 5 | ASND |
Ascendis Pharma A/S
|
1,958,843 | $448,046,159 | |
| 6 | XENE |
Xenon Pharmaceuticals Inc.
|
2,674,727 | $155,535,375 | |
| 7 | RAPP |
Rapport Therapeutics, Inc.
|
3,097,973 | $96,935,575 | |
| 8 | CYTK |
Cytokinetics Inc
|
1,338,803 | $88,240,505 |
All Filings in SYRE
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $88,074,746 | 1,746,129 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $114,415,643 | 3,492,541 | Shares | Defined | 2026-02-11 | |
| 2025-09-30 | $40,098,987 | 2,392,541 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $35,816,338 | 2,392,541 | Shares | Defined | 2025-08-13 | |
| 2025-03-31 | $38,603,649 | 2,392,541 | Shares | Defined | 2025-05-12 | |
| No filing history on record for this holder in this stock. | ||||||